Senior Consultant, A/Prof David Tan

• Senior Consultant, Department of Haematology-Oncology, National University Cancer Institute, Singapore
• Senior Consultant, Department of Oncology - Medical & Radiation, Ng Teng Fong General Hospital
• Associate Professor, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore

Qualifications:

BSc(Hons), MBBS(Hons)(London), PG Dip(Oncology), MRCP(UK)(Medical Oncology), PhD(London), FRCP(Edin)

Medical Oncology

Special Interests:

Gynaecologic Cancer, Drug Development/ Phase I Trials

Dr David Tan is a medical oncologist and clinician scientist at the National University Cancer Institute, Singapore. He is an Associate Professor at the Yong Loo Lin School of Medicine, NUS and Principal Investigator at the Cancer Science Institute, NUS. He is also Head of the Innovation Transfer Office at National University Health Systems (NUHS). His primary clinical and research interests are in gynaecological (ovarian, endometrial and cervical) cancers and the development of novel anti-cancer therapeutic agents.
Dr Tan graduated from Guy's, King's and St Thomas' School of Medicine, University of London, UK with a BSc in Experimental Pathology (1st Class Honours) and MBBS with Distinction. He undertook training in internal medicine at Hammersmith Hospital and Guy's and St Thomas' Hospitals in London before being awarded a Cancer Research UK Research Fellowship at The Institute of Cancer Research in London, where he obtained his PhD in Oncology. He subsequently completed his specialist training in medical oncology at The Royal Marsden Hospital in London. After working in the Drug Development Unit at The Royal Marsden Hospital/ Institute of Cancer Research, he completed another fellowship at the Princess Margaret Cancer Centre, University of Toronto, Canada, in Drug Development and Gynaecologic Oncology before returning back to Singapore.
He is the founding President of the Gynecologic Cancer Group Singapore (GCGS), which is a national clinical trials network for gynaecologic cancers in Singapore, and was the inaugural Chairman of the Asia-Pacific Gynaecologic Oncology Trials (APGOT) Group from . He currently also co-chairs the Cervical Cancer Research Network (CCRN) of the Gynecologic Cancer InterGroup (GCIG) and sits on the Gynecologic Cancer InterGroup (GCIG) Executive Board of Directors.

Awards

• 2018: NMRC Industry Alignment Fund Award (NMRC/MIAFC1/063/2018)
• 2019: Industry Alignment Fund Pre-positioning Award (SIGNAL) IAF-PP H19/01/a0/024

Journals & Publications

• Ngoi NY, Syn NL, Goh RM, Goh BC, Huang RYJ, Soon YY, James E, Cook A, Clamp A, Tan DS. Weekly versus tri-weekly paclitaxel with carboplatin for first-line treatment in women with epithelial ovarian cancer. The Cochrane database of systematic reviews 2:CD Feb 2022 (Journal Article)
• Bogani G, Ray-Coquard I, Concin N, Ngoi NYL, Morice P, Enomoto T, Takehara K, Denys H, Lorusso D, Coleman R, Tan DSP et al. Clear cell carcinoma of the endometrium Gynecologic Oncology 01 Jan 2022 (Journal Article)
• Wijaya ST, Ngoi NYL, Tan DSP. The role of molecular tests for adjuvant and post-surgical treatment in gynaecological cancers BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY 78:14- Jan 2022 (Journal Article)
• Pham MM, Ngoi NYL, Peng G, Tan DSP, Yap TA. Development of poly(ADP-ribose) polymerase inhibitor and immunotherapy combinations: progress, pitfalls, and promises Trends in Cancer 7(10):958- Oct 2021 (Journal Article)
• Ngoi NYL, Pham MM, Tan DSP, Yap TA. Targeting the replication stress response through synthetic lethal strategies in cancer medicine Trends in Cancer 7(10):930- Oct 2021 (Journal Article)
• Walsh RJ, Tan DSP. The Role of Immunotherapy in the Treatment of Advanced Cervical Cancer: Current Status and Future Perspectives JOURNAL OF CLINICAL MEDICINE 10(19):14 pages Number ARTN Oct 2021 (Journal Article)
• Jain SR, Sim W, Ng CH, Chin YH, Lim WH, Syn NL, Kamal NHBA, Gupta M, Heong V, Lee XW .Tan DSP. Statistical Process Control Charts for Monitoring Next-Generation Sequencing and Bioinformatics Turnaround in Precision Medicine Initiatives FRONTIERS IN ONCOLOGY 11:8 pages Number ARTN Sep 2021 (Journal Article)
• Heong V, Tan TZ, Miwa M, Ye J, Lim D, Herrington CS, Iida Y, Yano M, Yasuda M, Ngoi NYL , Tan DSP, Huang RYJ. A multi-ethnic analysis of immune-related gene expression signatures in patients with ovarian clear cell carcinoma JOURNAL OF PATHOLOGY 255(3):285- Sep 2021 (Journal Article)
• Mir SA, Wong SBJ, Narasimhan K, Esther CWL, Ji S, Burla B, Wenk MR, Tan DSP, Bendt AK. Lipidomic Analysis of Archival Pathology Specimens Identifies Altered Lipid Signatures in Ovarian Clear Cell Carcinoma METABOLITES 11(9):12 pages Number ARTN Sep 2021 (Journal Article)
• Nin DS, Wujanto C, Tan TZ, Lim D, Damen JMA, Wu K-Y, Dai ZM, Lee Z-W, Idres SB, Leong YH , .Tan DSP, Wu W, Choo, BA, Ding LW. GAGE mediates radio resistance in cervical cancers via the regulation of chromatin accessibility CELL REPORTS 36(9):25 pages Number ARTN Aug 2021 (Journal Article)

Professional Memberships

• American Society of Clinical Oncology
• The Royal College of Physicians, London, UK